[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Triptorelin.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Triptorelin.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Triptorelin.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Triptorelin.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Triptorelin.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Triptorelin.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Triptorelin.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Triptorelin.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Eribulin.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Triptorelin.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Triptorelin.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Triptorelin.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triptorelin.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Triptorelin.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Triptorelin.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Triptorelin.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Triptorelin.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Triptorelin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Vandetanib.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Triptorelin.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Triptorelin.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Triptorelin.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Triptorelin.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triptorelin.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ziprasidone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Triptorelin.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Triptorelin.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Atropine.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Triptorelin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mirabegron.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Triptorelin.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Triptorelin.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Triptorelin.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Moxifloxacin.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Triptorelin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Triptorelin.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Triptorelin.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Benzyl alcohol.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bepridil.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Triptorelin.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Triptorelin.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Triptorelin.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Triptorelin.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Olodaterol.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Eliglustat.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Triptorelin.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Triptorelin.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Panobinostat.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ivabradine.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Triptorelin.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Triptorelin.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Triptorelin.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Triptorelin.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Triptorelin.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Triptorelin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bupranolol.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Triptorelin.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Triptorelin.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Triptorelin.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Triptorelin.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Oxybuprocaine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Delafloxacin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Triptorelin.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Efavirenz.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Triptorelin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Triptorelin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Macimorelin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Carbinoxamine.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Encorafenib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Triptorelin.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ivosidenib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Triptorelin.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Triptorelin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Chloroprocaine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Inotersen.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Triptorelin.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Triclabendazole.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Clarithromycin.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cicletanine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Entrectinib.]
[N07XX11, pitolisant, Triptorelin may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Triptorelin.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Triptorelin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Triptorelin.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dexchlorpheniramine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Triptorelin.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chlorcyclizine.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fostemsavir.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triptorelin.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Triptorelin.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Relugolix.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Triptorelin.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Flumequine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Triptorelin.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Triptorelin.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Triptorelin.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Triptorelin is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Clemastine.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Triptorelin.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Triptorelin.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Triptorelin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Clomipramine.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Triptorelin.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Triptorelin.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Triptorelin.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Cocaine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Triptorelin.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Triptorelin.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Triptorelin.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Triptorelin.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Desloratadine.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Triptorelin.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Emedastine.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Triptorelin.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Triptorelin.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Triptorelin.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Triptorelin.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lomefloxacin.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Triptorelin.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Adenosine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Triptorelin.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Melperone.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Triptorelin.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Triptorelin.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Triptorelin.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Triptorelin.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Triptorelin.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Triptorelin.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxaliplatin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Cinchocaine.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Triptorelin.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Triptorelin.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Erlotinib.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Triptorelin.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Triptorelin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Triptorelin.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Triptorelin.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Triptorelin.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dimenhydrinate.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Diphenhydramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cisapride.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Triptorelin.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Triptorelin.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Triptorelin.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Triptorelin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Triptorelin.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Triptorelin.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Triptorelin.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Triptorelin.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Triptorelin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Triptorelin.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Triptorelin.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Droperidol.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sultopride.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Temafloxacin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Terodiline.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Triptorelin.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Toremifene.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pipemidic acid.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Triptorelin.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Triptorelin.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Triptorelin.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Triptorelin.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Triptorelin.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Erythromycin.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Triptorelin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Etidocaine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Triptorelin.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Triptorelin.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Triptorelin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Terfenadine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Triptorelin.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Triptorelin.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Triptorelin.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fendiline.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Triptorelin.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Flecainide.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Triptorelin.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Triptorelin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Flupentixol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fluspirilene.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Triptorelin.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Triptorelin.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Gallopamil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Triptorelin.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Triptorelin.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Triptorelin.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Triptorelin.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Triptorelin.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Triptorelin.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Triptorelin.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Triptorelin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dofetilide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Triptorelin.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Triptorelin.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Triptorelin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Quetiapine.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Triptorelin.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Triptorelin.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Triptorelin.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Triptorelin.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Hydroxyzine.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Triptorelin.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Triptorelin.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Triptorelin.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Triptorelin.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Triptorelin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Anagrelide.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Triptorelin.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Triptorelin.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Triptorelin.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Triptorelin.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nalidixic acid.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Triptorelin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lidoflazine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Loperamide.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Triptorelin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Triptorelin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Mepivacaine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Methadone.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Triptorelin.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Triptorelin.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Triptorelin.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Triptorelin.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Amitriptyline.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pazopanib.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Triptorelin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Triptorelin.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Triptorelin.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Triptorelin.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Triptorelin.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Iloperidone.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Triptorelin.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nimodipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Triptorelin.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Triptorelin.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Triptorelin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triptorelin.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ofloxacin.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxolinic acid.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triptorelin.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Asenapine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Papaverine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Triptorelin.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Penfluridol.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Triptorelin.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Triptorelin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Triptorelin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pimozide.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Saquinavir.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Grepafloxacin.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Triptorelin.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Triptorelin.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Triptorelin.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Triptorelin.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Prajmaline.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Primaquine.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Procaine.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Prochlorperazine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Triptorelin.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Propafenone.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Triptorelin.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Triptorelin.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Triptorelin.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Triptorelin.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Triptorelin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Roxithromycin.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sotalol.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Valproic acid.]
